Wealth Enhancement Advisory Services LLC Sells 10,139 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

Wealth Enhancement Advisory Services LLC lessened its stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 22.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 35,134 shares of the biotechnology company’s stock after selling 10,139 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Heron Therapeutics were worth $54,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of HRTX. Principal Financial Group Inc. boosted its position in Heron Therapeutics by 10.6% during the 4th quarter. Principal Financial Group Inc. now owns 113,560 shares of the biotechnology company’s stock valued at $174,000 after acquiring an additional 10,909 shares in the last quarter. New York State Common Retirement Fund boosted its position in Heron Therapeutics by 3.2% during the 4th quarter. New York State Common Retirement Fund now owns 1,321,006 shares of the biotechnology company’s stock valued at $2,021,000 after acquiring an additional 41,062 shares in the last quarter. Cutter & CO Brokerage Inc. boosted its position in Heron Therapeutics by 69.6% during the 4th quarter. Cutter & CO Brokerage Inc. now owns 33,135 shares of the biotechnology company’s stock valued at $51,000 after acquiring an additional 13,600 shares in the last quarter. Anfield Capital Management LLC boosted its position in Heron Therapeutics by 5.6% during the 4th quarter. Anfield Capital Management LLC now owns 118,976 shares of the biotechnology company’s stock valued at $182,000 after acquiring an additional 6,264 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Heron Therapeutics by 0.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,105,803 shares of the biotechnology company’s stock valued at $1,692,000 after acquiring an additional 9,418 shares in the last quarter. Institutional investors own 80.01% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on HRTX shares. Needham & Company LLC reiterated a “buy” rating and set a $4.00 price objective on shares of Heron Therapeutics in a report on Friday, April 11th. Wall Street Zen upgraded Heron Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, June 6th. Finally, HC Wainwright started coverage on Heron Therapeutics in a report on Monday, June 9th. They set a “buy” rating and a $6.00 price objective for the company.

Heron Therapeutics Trading Up 2.6%

Shares of HRTX opened at $2.00 on Thursday. The firm has a market cap of $305.12 million, a PE ratio of -33.33 and a beta of 1.15. The stock has a fifty day moving average price of $2.03 and a 200-day moving average price of $1.91. Heron Therapeutics, Inc. has a 12 month low of $1.04 and a 12 month high of $3.73.

Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.02. The firm had revenue of $38.90 million during the quarter, compared to analysts’ expectations of $37.08 million. As a group, research analysts forecast that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.